Apitope hires Dr. Graham Roberts as Development Director for Therapeutics
Apitope International N.V. announced the appointment of Dr. Graham Roberts as Development Director for Therapeutics. Among his responsibilities at Apitope, Dr Roberts will have overall responsibility for Apitope's R&D activities with an initial focus on the ATX-MS-1467 project. In January, Apitope signed a development and commercialization deal with Merck Serono to develop ATX-MS-1467, a targeted approach to treat multiple sclerosis.
Dr. Roberts joins Apitope from SRA GCD Ltd (formerly, Constella Group Ltd), which he joined in 2004 and was promoted to Global VP of Regulatory Affairs & Strategic Drug Development Services in early 2009.
Dr. Roberts will be reporting directly to Dr. Martin and will also work on advancing Apitope's growing portfolio in other autoimmune diseases areas.
From 1991 to 2004, Dr. Roberts worked with British Biotech in a number of roles; latterly as Project Director & Biologics Manufacturing Manager. Earlier, he was a Group Manager within research at Celltech Group. Dr. Roberts obtained his PhD. in the Biochemistry Department at the University of Cambridge.
Most read news
Topics
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
Epistem Announces Partnership with The University of Manchester
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents
High-Tech Gründerfonds, Bayern Kapital and BioM AG to invest in Intana Bioscience GmbH

Heart hormone helps shape fat metabolism - Sanford-Burnham study shows that the pathway to losing fat is heavily influenced by a hormone produced in the heart
Low-carb diets linked to atherosclerosis and impaired blood vessel growth - Study suggests that popular diet regimen may have adverse effect on body's restorative capacity

Autoimmunity: immune cells escape therapy due to "exhausted" state - Researchers have succeeded in isolating and analyzing disease-causing T cells from the blood in autoimmune diseases
Fluidity Predicts Aggressiveness of Cancerous Tumours
Biogemma and Wageningen UR announce a collaboration in wheat drought tolerance research
Harvard Apparatus Acquires PanLab s.l. - A New Acquisition by Harvard Apparatus Expands its Behavioral Sciences Product Offerings

SCIO Automation Munich GmbH - Frankenthal, Germany
